Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B), while Vanguard Total World Stock Index Fund ETF trades at $159.53 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| REGN | VT | |
|---|---|---|
Market Cap | $76.14B | $101.70B |
Volume | 500,239 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $852.03 | $162.39 |
52-Week Low | $557.73 | $134.19 |
Typical Hold Time | 107 Days | 53 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
VT trades at $159.64, down 0.66% on the day, with technical indicators showing a bullish bias in moving averages while oscillators remain neutral. The ETF maintains strong global diversification with over 9,700 stocks across developed and emerging markets. Recent news highlights VT's competitive positioning against international-focused ETFs, with Seeking Alpha maintaining a Buy rating and targeting 6-10% returns over the next 6-12 months.
VT offers comprehensive global equity exposure with a low 0.06% expense ratio, though key financial ratios remain unavailable. The outlook remains positive for long-term diversification, with risks including currency fluctuations and geopolitical tensions. Institutional activity shows mixed signals with both position increases and decreases reported in recent quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
